Subscribe to Blog via Email
What is von Hippel-Lindau disease (VHL)?
Von Hippel-Lindau disease (VHL) is an autosomal dominant disease that can predispose individuals to multiple neoplasms. Germline pathogenic variants in the VHL gene predispose individuals to specific types of benign tumors, malignant tumors, and cysts in many organ systems. These include central nervous system hemangioblastomas; retinal hemangioblastomas; clear cell renal cell carcinomas and renal cysts; pheochromocytomas, cysts, cystadenomas, and neuroendocrine tumors of the pancreas; endolymphatic sac tumors; and cystadenomas of the epididymis.
What is Belzutifan (Welireg)?
It is an oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor. As an inhibitor of HIF-2α, belzutifan reduces transcription and expression of HIF-2α target genes associated with cellular proliferation, angiogenesis and tumor growth.
On August 13 2021, FDA approved belzutifan (Welireg) to treat adults who have several tumors associated with VHL. Specifically, the drug is approved to treat VHL-associated renal cell carcinoma (a type of kidney cancer), central nervous system hemangioblastomas (a type of noncancerous tumor that forms in the brain or spinal cord), and pancreatic neuroendocrine tumors that don’t require immediate surgery.
This is the first US FDA approved treatment for VHL
What about Pheochromocytoma/Paraganglioma (Pheo/Para)?
Those who know the linkages between pheo/para and VHL will have spotted that was missed from the FDA approval wording. I have no idea at this time but will continue researching to see why the drug was not suitable/approved for this associated tumour group. According to the US NIH, approximately 10% to 20% of people with VHL will develop pheochromocytoma.
(But see related clinical trial information below).
What about non VHL associated pancreatic NET?
This question actually came up in my private patient group. It’s a great question.
(But see related clinical trial information below).
Trials for Pheo/Para and Pancreatic NET with or without the VHL connection
Given the VHL linkages above to both of these groups of NETs, clearly scientists are looking to see if this drug has any efficacy in sporadic versions.
Just as Belzutifan was about to be approved, a new clinical trial was scheduled under ClinicalTrials.gov Identifier: NCT04924075. The key difference is that this trial is to evaluate the efficacy and safety of Belzutifan monotherapy in participants with advanced pheo/para and pNET or von Hippel-Lindau (VHL) Disease-Associated Tumors in 3 different cohorts. The third cohort for VHL will also include VHL related pheo/para and pNET patients. The primary objective of the study is to evaluate the objective response rate (ORR) of belzutifan per RECIST 1.1) by blinded independent central review (BICR).
This is an international trial taking place in many European, North American and Asian countries.
Why is this trial important?
It would provide another outlet for treatment of sporadic Pancreatic NET and Pheo/Para. But it would also add Pheo/Para to the VHL associated approvals list.
Read more here
1. FDA Approval of Belzutifan – click here
2. ClinicalTrials.gov Identifier: Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), or Von Hippel-Lindau (VHL) Disease-Associated Tumors (MK-6482-015) – Full Text View – ClinicalTrials.gov
General Clinical Trials Disclaimer
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided in the clinical trials document. It’s very important to check the trial inclusion and exclusion criteria before making any contact. If you need questions, the articles here is very useful Questions to Ask About Clinical Trials | Cancer.Net
The inclusion of any trial within this blog should not be taken as a recommendation by Ronny Allan.
I am not a doctor or any form of medical professional, practitioner or counsellor. None of the information on my website, or linked to my website(s), or conveyed by me on any social media or presentation, should be interpreted as medical advice given or advised by me. Neither should any post or comment made by a follower or member of my private group be assumed to be medical advice, even if that person is a healthcare professional as they are not members of the private group or followers of my sites in any official capacity. Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over the counter drugs and supplements such as vitamins and minerals.
Whenever I post about a trial or study, some people get excited without understanding that these new treatments and capabilities can very often take years to come to fruition and it’s also possible that clinical trials can be halted, or that national approval agencies will not approve the final product. Plus, not everyone will be eligible, so always check the exclusion and inclusion criteria in the relevant clinical trials document. Please bear that in mind when reading studies/clinical trials posted on RonnyAllan.NET
Top 10 Posts & Pages in the last 48 hours (auto updates) (Click the titles to read them)
Thanks for reading.
Sign up for my newsletters – Click Here
Check out my Glossary of Terms – click here
Please Share this post for Neuroendocrine Cancer awareness and to help another patient
UPDATE – Sep 25th, 2023 – Novartis radioligand therapy Lutathera® demonstrated statistically significant and clinically meaningful progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors
Whenever I get a chance to talk to a pharma involved in somatostatin analogue injection devices, I tell them one very important thing …… “To
Update August 2023. Latest CT surveillance scan reports “No evidence of progressive disease at any site”. Very pleased! With incurable but treatable cancers such as
US singer-songwriter Jimmy Buffett, best known for his 1970’s hit Margaritaville, has died aged 76. “Jimmy passed away peacefully on the night of September 1
September is Childhood Cancer Awareness Month! The newspapers and social media will no doubt be featuring many childhood cancer articles. You may not see one
On my website RonnyAllan.NET, August was as quiet as July but in the second half, I accelerated publication of some posts. The month was also